Thursday May 25th 2017

Posts Tagged ‘Petition’

Martin from MS-CCSVI-UK.org on Sky News talking about CCSVI

Martin from MS-CCSVI-UK.org on Sky News talking about CCSVI

www.ms-ccsvi-uk.org committed to raising awareness of CCSVI in the UK please sign our petition to bring CCSVI research into the UK: petitions.number10.gov.uk thank you Posted by Mark [Read More]

CCSVI Who are we fighting, will you be heard?

CCSVI Who are we fighting, will you be heard?

Where is the media coverage for CCSVI, who will speak up for us, how do we get more research done as a group How do we come together? Here is a link to a petition I started www.gopetition.com www.facebook.com Huffington Post article and this vlog mentioned [Read More]

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]